Scrip is at Rs 691 having risen handsomely with good volumes after a full fledged correction and hibernating for quite some time. With USFDA behind it and a good number of ANDAs in the offing and due for sanction from USFDA in the coming year, it is sure to catapult to much newer heights. Resistance being at Rs 725 ~ 750, a breather and then a sustained rise to Rs 1050+ cannot be ruled out. Buy and hold with a stoploss of Rs. 665 or so.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.